Share：
Share this content in WeChat
X
[Chinese][PDF]70781
• Editorial •
Clinical value of functional MRI in assessment of early response to neoadjuvant chemotherapy in breast carcinoma
WANG Xiao-hong  LI Rui-min  PENG Wei-jun 

DOI:10.3969/j.issn.1674-8034.2011.03.003.


[Abstract] Functional MRI (fMRI) includes diffusion weighted imaging (DWI), 1H proton magnetic resonance spectroscopy (1H-MRS), and quantitative dynamic enhanced MRI. These imaging methods can predict early response to neoadjuvant chemotherapy (NAC) in patients with locally advanced breast cancer (LABC) by monitoring vascular supply of tumor and pathological response early after the initiation of treatment. Therefore, fMRI may bring benefits for clinical therapeutic strategy optimization. Combination of different fMRI methods is useful to evaluate early response to NAC.
[Keywords] Magnetic resonance imaging；Breast cancer；Neoadjuvant chemotherapy

WANG Xiao-hong Department of Diagnostic Radiology, Cancer Center, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

LI Rui-min Department of Diagnostic Radiology, Cancer Center, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

PENG Wei-jun* Department of Diagnostic Radiology, Cancer Center, Fudan University, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

*Correspondence to: Peng WJ, E-mail: cjr.pengweijun@vip.163.com

Conflicts of interest   None.

Received  2011-03-23
Accepted  2011-04-28
DOI: 10.3969/j.issn.1674-8034.2011.03.003
DOI:10.3969/j.issn.1674-8034.2011.03.003.

[1]
Charfare H, Limongelli S, Purushotham AD, et al. Neoadjuvant chemotherapy in breast cancer. Br J Surg, 2005, 92(1):14-23.
[2]
Partridge SC, Gibbs JE, Lu Y, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol, 2005, 184(6):1774-1781.
[3]
Roben SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res, 2001, 3(1):36-40.
[4]
Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am, 2006, 14(3):383-389.
[5]
Junkermann H, Fournier D von. Imaging procedures for assessment of the response of mammary carcinoma to preoperative chemotherapy. Radiology, 1997, 37(9):726-732.
[6]
Pickles MD, Gibbs P, Lowry M, et al. Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging, 2006, 24(7):843-847.
[7]
Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer, 2002, 38(16): 2116-2127.
[8]
Cocquyt VF, Villeirs GM, Blondeel PN, et al. Assessment of response to preoperative chemotherapy in patients with stage II and III breast cancer: the value of MRI. Breast, 2002, 11(4): 306-315.
[9]
Chenevert TL, Stegman LD, Taylor JMG, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst, 2000, 92(24):2029-2036.
[10]
Galons JP, Altbach MI, Paine-Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia, 1999, 1(2):113-117.
[11]
Lee KC, Moffat BA, Schott AF, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res, 2007, 13(2Pt 1):443-50.
[12]
Balu MC, Chapellier C, Bleuse A, et al. Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Research and Treatment, 2002, 72(2):145-152.
[13]
Mardor Y, Roth Y, Ocherashvilli A, et al. Pretreatment prediction of brain tumors' response to radiation therapy using high B-value diffusion-weighted MRI. Neoplasia, 2004, 6(2):136-142.
[14]
Davis PL, Staiger MJ, Harris KB, et al. Breast cancer measurements with magnetic resonance imaging, ultrasonography and mammography. Breast Cancer Res Treat, 1996, 37(1):1-9.
[15]
George ML, Dzik-Jurasz ASK, Padhani AR, et al. Non-invasive methods of assessing angiogenesis and their value in predicting response totreatment in colorectal cancer. Br J Surg, 2001, 88(12):1628-1636.
[16]
Hylton N. MR imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am, 2006, 14(3):383-389.
[17]
Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res, 2001, 3(1):36-40.
[18]
Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology, 1997, 204(3):661-666.
[19]
Gribbestad IS, Sitter B, Lundgren S, et al. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res, 1999, 19(3A):1737-1746.
[20]
Podo F. Tumor phospholipid metabolism. NMR in Biomedicine, 1999, 12(7):413-439.
[21]
Glunde K, Jie C, Bhujwalla ZM, et al. Molecular causes of the Aberrant Choline Phospholipid metabolism in breast cancer. Cancer Research, 2004, 64(12):4270-4276.
[22]
Cheng LL, Chang W, Smith BL, et al. Evaluating human breast ductal carcinomas with high-resolution magicanglespinning proton magnetic resonance spectrscopy. J Magn Reson, 1998, 135(1):194-202.
[23]
Roebuck JR, Cecil KM, Schnall MD, et al. Human breast lesions: characterization with proton MR spectroscopy. Radiology, 1998, 209(1):269-275.
[24]
Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo 1H NMR spectra with increased magnetic field strength. J Magn Reson Imaging, 1999, 10(2):159-164.
[25]
Wolf W, Waluch V, Presant CA. Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. NMR Biomed, 1998, 11(7):380-387.
[26]
Jagannathan NR, Kumar M, Seenu V, et al. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer, 2001, 84(8):1016-1022.
[27]
Griffiths JR, Glickson JD. Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy. Adv Drug Deliv Rev, 2000, 41(1):75-89.
[28]
Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy-A Pilot Study at 4 T. Radiology, 2004, 233(2):424-431.
[29]
Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med，2004, 51(4):858-862.
[30]
Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging, 2007, 25(1):1-13.
[31]
Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging, 1999, 10(3):223-232.
[32]
Semple SI, Harry VN, Parkin DE, et al. A combined pharmacokinetic and radiologic assessment of dynamic contrast-enhancement magnetic resonance imaging predicts response to chemoradiation in locally advanced cervical cancer. Int Radiat Oncol Biol Phys, 2009, 75(2):611-617.
[33]
Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging, 1997, 7(1):91-101.
[34]
Huang W, Li X, Morris EA, et al. The magnetic resonance shutter speed discriminates vascular properties of malignant and benign breast tumors in vivo. Proc Natl Acad Sci USA, 2008, 105(46): 17943-17948.

PREV Value of MRI follow-up in breast cancer’s diagnosis and efficacy evaluation
NEXT Sequence and scanning parameter optimization for breast MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn